130464-88-9

Usage

Uses

Used in Pharmaceutical Industry:
(2R)-2-bromo-4-methylpentanoic acid t-butyl ester is used as a pharmaceutical intermediate for the synthesis of various drugs and medicinal compounds. Its unique structure and properties make it a valuable building block in the development of new pharmaceuticals.
Used in Chemical Research:
(2R)-2-bromo-4-methylpentanoic acid t-butyl ester is used as a research compound in the field of chemistry. Its versatility and potential applications in various reactions and processes make it an important tool for scientists and researchers.
Used in Organic Synthesis:
(2R)-2-bromo-4-methylpentanoic acid t-butyl ester is used as a reagent in organic synthesis, where it can be employed to produce a variety of organic compounds. Its t-butyl ester group provides stability and protection to the carboxylic acid moiety, making it easier to handle and use in chemical reactions.

Upstream product

• 42990-28-3 (R)-2-bromo-4-methylpentanoic acid 
• 7664-93-9 sulfuric acid 
• 115-11-7 isobutene 

Downstream Products

• 145660-99-7 2-Benzyloxycarbonyl-3R-isobutyl-succinic acid 4-tert-butyl ester 1-benzyl ester 
• 209978-18-7 (2R)-2-[(1-methoxy-carbonyl-1-benzyloxycarbonyl)methyl]-4-methylpentanoic acid t-butyl ester 
• 168158-38-1 (2R,3S)-N⁴-Benzyloxy-2-isobutyl-3-methyl-N¹-((S)-methylcarbamoyl-phenyl-methyl)-succinamide 
• 168158-16-5 (2R,3R)-N⁴-Hydroxy-2-isobutyl-3-methyl-N¹-((S)-methylcarbamoyl-phenyl-methyl)-succinamide 
• 168158-16-5 KB-R₇₇₈₅ 
• 188728-97-4 (R)-2,5-Dimethyl-3-[((S)-methylcarbamoyl-phenyl-methyl)-carbamoyl]-hexanoic acid 
• 188728-83-8 (R)-2-(3,4-Dihydro-1H-isoquinolin-2-ylmethyl)-5-methyl-3-((S)-1-methylcarbamoyl-2-naphthalen-1-yl-ethylcarbamoyl)-hexanoic acid benzyl ester 
• 188729-13-7 2-[(R)-3-Methyl-1-((S)-1-methylcarbamoyl-2-naphthalen-1-yl-ethylcarbamoyl)-butyl]-malonic acid dibenzyl ester 
• 190909-32-1 (2R,3R)-N¹-Benzyloxy-2-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-3-isobutyl-N⁴-((S)-methylcarbamoyl-phenyl-methyl)-succinamide 
• 190909-11-6 (2R,3R)-N⁴-Benzyloxy-2-isobutyl-N¹-((S)-methylcarbamoyl-phenyl-methyl)-3-(4-methyl-piperazin-1-ylmethyl)-succinamide 
• 168158-24-5 (2R,3R)-N⁴-Benzyloxy-2-isobutyl-N¹-((S)-methylcarbamoyl-phenyl-methyl)-3-morpholin-4-ylmethyl-succinamide 
• 168158-25-6 2-{(R)-3-Methyl-1-[((S)-methylcarbamoyl-phenyl-methyl)-carbamoyl]-butyl}-malonic acid dibenzyl ester 
• 155947-71-0 benzyl 2<(benzyloxy)carbonyl>-3(R)-(hydroxycarbonyl)-5-methylhexanoate 

Relevant academic research and scientific papers

Matrix metalloprotease inhibitors

Compounds of formula (I): STR1 as single stereoisomers or mixtures thereof and their pharmaceutically acceptable salts inhibit matrix metalloproteases, such as interstitial collagenases, and are useful in the treatment of mammals having disease states alleviated by the inhibition of such matrix metalloproteases, for example arthritic diseases or bone resorption disease, such as osteoporosis.

MATRIX METALLOPROTEASE INHIBITORS

Compounds of formula (I): STR1 as single stereoisomers or mixtures thereof and their pharmaceutically acceptable salts inhibit matrix metalloproteases, such as interstitial collagenases, and are useful in the treatment of mammals having disease states alleviated by the inhibition of such matrix metalloproteases, for example arthritic diseases or bone resorption diseases, such as osteoporosis.

Synthesis and biological evaluation of orally active matrix metaloproteinase inhibitors

The synthesis and biological evaluation of orally active inhibitors of matrix metalloproteinase are reported. Modifications of the P2' position and the α-substituent of hydroxamic acid derivatives were carried out, and revealed that the P2' substituent influenced the MMP inhibitory activities in vitro and in plasma after oral administration. The hydroxamates with phenylglycine at the P2' position were absorbed well orally. Compound 15e, which exhibited the longest duration of inhibitory activity in plasma after oral administration among the phenylglycine derivatives (5a-5d, 15a, 15c, 15e), was evaluated in a rat adjuvant arthritis model. A reduction in hind foot pad swelling and improvements of some inflammatory parameters were demonstrated when the compound was administered orally. These results indicate the potential of MMP inhibitors for rheumatoid arthritis.